Advertisement
U.S. Markets closed

Minerva Neurosciences, Inc. (NERV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.6700+0.0100 (+0.38%)
At close: 04:00PM EDT
2.6700 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.6600
Open2.6000
Bid1.8600 x 200
Ask3.3600 x 200
Day's Range2.5684 - 2.6747
52 Week Range2.2600 - 13.4900
Volume21,818
Avg. Volume15,503
Market Cap18.672M
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)-4.4000
Earnings DateNov 05, 2024 - Nov 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • Associated Press Finance

    Minerva Neurosciences: Q2 Earnings Snapshot

    BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported a loss of $8.2 million in its second quarter.

  • GlobeNewswire

    Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

    BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the second quarter of 2024 ending June 30, 2024. Roluperidone NDA Update During the first quarter of this year, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Let